ArticleHeliyon2023
Isolation and identification of a novel vardenafil analogue, propoxy-vardenafil, found as an adulterant in a health supplement.
Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A novel vardenafil analogue was detected from a health wine claimed to be anti-impotence during a special inspection in an online store. Methods: The unknown compound was found by using ultra-high performance liquid chromatography coupled to quadrupole time of flight mass spectrometry (UHPLC/Q-TOF MS). The characteristic product ions were similar to those of vardenafil. The UV spectrum of the compound closely mirrored that of vardenafil. The analogue underwent purification by semi-preparative HPLC and structurally identified by FT-IR and NMR analysis. Results: Based on the data, The structure of the analogue was characterized as 2-[2-propyloxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-3H-imidazo [5,15,1-f] [1,2,4]triazin-4-one, simplified as propoxy-vardenafil. Conclusion: To the best of our knowledge, the analogue has not been reported and is even only ninth vardenafil analogue, which was confirmed that a n-propyloxy group had replaced the ethoxy group on the aromatic ring of vardenafil. Therefore, It is essential to pay more attention to vardenafil analogues in the routine inspection of health supplements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.